论文部分内容阅读
目的探讨诺和锐30联合罗格列酮治疗初发2型糖尿病的疗效及安全性。方法将60例初发2型糖尿病患者随机分为治疗组和对照组,每组30例。治疗组用诺和锐30联合罗格列酮4 mg/d;对照组单用诺和锐30治疗。随访12周,观测体重、BMI、空腹血糖(FBG)、糖化血红蛋白(HbA1c)、胰岛素用量及药物不良反应。结果诺和锐30联合罗格列酮治疗组比对照组有更好的治疗效果,且胰岛素用量明显减少,低血糖发生率、空腹血糖和糖化血红蛋白水平均较对照组明显降低,差异有统计学意义。结论诺和锐30联合罗格列酮治疗2型糖尿病患者可以进一步降低血糖和糖化血红蛋白,是2型糖尿病患者安全有效的治疗方案。
Objective To investigate the efficacy and safety of Novolinol 30 combined with rosiglitazone in the treatment of newly diagnosed type 2 diabetes mellitus. Methods Sixty patients with newly diagnosed type 2 diabetes were randomly divided into treatment group and control group, 30 cases in each group. The treatment group with Novo Rui 30 combined with rosiglitazone 4 mg / d; the control group with Novo Rui 30 treatment. After 12 weeks of follow-up, body weight, BMI, fasting blood glucose (FBG), HbA1c, insulin dosage and adverse drug reactions were observed. Results Novo-Rui 30 combined with rosiglitazone treatment group than the control group has a better therapeutic effect, and the amount of insulin was significantly reduced, the incidence of hypoglycemia, fasting blood glucose and glycosylated hemoglobin levels were significantly lower than the control group, the difference was statistically significant significance. Conclusions Nuo-Rui-Ru-30 combined with rosiglitazone can further reduce blood glucose and HbA1c in type 2 diabetic patients and is a safe and effective treatment for type 2 diabetic patients.